The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.

Exclusion Criteria

• •In order to participate in this study, a patient MUST NOT:
• •1. Have a baseline glomerular filtration rate \< 50 ml/min1.73m2.
• •2. Have a known, serious radiographic contrast allergy.
• •3. Have a mechanical aortic valve or heart constrictive device.
• •4. Have a documented presence of aortic stenosis (aortic stenosis graded as ≥ +2 equivalent to an orifice area of 1.5cm2 or less).
• •5. Have a documented presence of moderate to severe aortic insufficiency (echocardiographic assessment of aortic insufficiency graded as ≥+2).
• •6. Require coronary artery revascularization. Patients who require or undergo revascularization procedures should undergo these procedures a minimum of 3 months in advance of treatment within this study. In addition, patients who develop a need for revascularization following enrollment will be submitted for this therapy without delay.
• •7. Evidence of a life-threatening arrhythmia (nonsustained ventricular tachycardia ≥ 20 consecutive beats or complete heart block) or QTc interval \> 550 ms on screening ECG.
• •8. AICD firing in the past 60 days prior to the procedure.
• •9. Have unstable angina within 2 weeks of the planned procedure.
• •10. Have a hematologic abnormality as evidenced by hematocrit \< 25%, white blood cell \< 2,500/ul or platelet values \< 100,000/ul without another explanation.
• •11. Have liver dysfunction, as evidenced by enzymes (AST and ALT) greater than three times the ULN.
• •12. Have a coagulopathy = (INR \> 1.3) not due to a reversible cause (i.e., Coumadin). Patients on Coumadin will be withdrawn 5 days before the procedure and confirmed to have an INR \< 1.3. Patients who cannot be withdrawn from Coumadin will be excluded from enrollment
• •13. Have known allergies to penicillin or streptomycin.
• •14. Have a contra-indication to performance of an MRI scan.
• •15. Be an organ transplant recipient.
• •16. Have a clinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease free for 5 years), except curatively-treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma.
• •17. Have a non-cardiac condition that limits lifespan to \< 1 year.
• •18. Have a history of drug or alcohol abuse within the past 24 months.
• •19. Be on chronic therapy with immunosuppressant medication, such as corticosteroids or TNFα antagonists.
• •20. Be serum positive for HIV, hepatitis BsAg or hepatitis C.
• •21. Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.
• •22. Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female patients must undergo a blood or urine pregnancy test at screening and within 36 hours prior to injection.